首页> 外文OA文献 >Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

【2h】

Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

机译：矫正：对Nivolumab Plus IpiLimumab的生存结果和独立的反应评估与晚期肾细胞癌患者的孙替替尼：42个月的随机阶段3临床试验随访

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial [J] . Robert J Motzer, Bernard Escudier, David F McDermott, Journal for ImmunoTherapy of Cancer . 2020,第2期

机译：患有Nivolumab Plus IpiLimumab与Sunitinib在晚期肾细胞癌的患者中的生存结果和独立反应评估：42个月的随机阶段3临床试验
2. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial [J] . Cella David, Gruenwald Viktor, Escudier Bernard, The lancet oncology . 2019,第2期

机译：用Nivolumab Plus Ipilimumab治疗的患者晚期肾细胞癌的患者的患者的结果（Cheedmate 214）：随机，第3阶段试验
3. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial (vol 20, pg 297, 2019) [J] . Cella D., Grunwald V, Escudier B. The lancet oncology . 2019,第6期

机译：患有Nivolumab Plus IpiLimumab的晚期肾细胞癌患者的患者报告的患者的结果（Cheemate 214）：A随机，第3阶段试验（Vol 20，PG 297,2019）
4. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial [O] . Robert J Motzer, Bernard Escudier, David F McDermott, 2020

机译：患有Nivolumab Plus IpiLimumab与Sunitinib在晚期肾细胞癌的患者中的生存结果和独立反应评估：42个月的随机阶段3临床试验
5. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial [O] . Robert J Motzer, Bernard Escudier, David F McDermott, 2020

机译：患有Nivolumab Plus IpiLimumab与Sunitinib在晚期肾细胞癌的患者中的生存结果和独立反应评估：42个月的随机阶段3临床试验

Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

著录项

引文网络

相似文献

相关主题

期刊订阅